[Chemotherapy for gliomas based on the expression levels of drug resistant genes].

Abstract

Drug resistance, which often occurs during chemotherapy, is still a great obstacle to the success of human malignancy treatment. Among many possible mechanisms of drug resistance (biological, biochemical, kinetic or pharmacological), both typical and atypical multidrug-resistance (MDR) have been extensively studied. We picked up MDR-1, MXR, MRP1, MRP2, TopoII alpha, MGMT, and GST-pi as drug-resistant gene, based on experimental data and previous reports. Expression of these genes were measured in 14 malignant glioma specimens by reverse transcription polymerase chain reaction assay. We chose anticancer drugs for each patient, based on results of drug resistant gene expression to acquire good response to drugs. Though our follow-up periods are not long enough to analyze the results of our chemotherapy, 78% (7/9) of our glioma patients who were treated with our chemotherapy are free from tumor progression. The assays, which measure the expression of drug resistant genes, are necessary to allow rapid detection of the drug-sensitivity to chemotherapy in malignant glioma patients.

• Authors: Y Matsumoto, K Morisaki, K Miyake, M Kawanishi, N Kawai, T Ogawa, K Irie, K Kunishio, S Nagao
• Journal: No shinkei geka. Neurological surgery (No Shinkei Geka) Vol. 29 Issue 7 Pg. 625-30 (Jul 2001) ISSN: 0301-2603 [Print] Japan
• PMID: 11517503 (Publication Type: English Abstract, Journal Article)

Chemical References

• Antineoplastic Agents

Topics

• Adult
• Aged
• Antineoplastic Agents (pharmacology)
• Brain Neoplasms (drug therapy, genetics)
• Drug Resistance, Neoplasm (genetics)
• Female
• Genes, MDR
• Glioma (drug therapy, genetics)
• Humans
• Male
• Middle Aged
• Reverse Transcriptase Polymerase Chain Reaction